Farmacovigilancia intensiva de infliximab en un hospital general

• Autores: E. Márquez Saavedra, Silvia Artacho Criado
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 5, Nº. 3, 2003, págs. 136-144
• Idioma: español
• Títulos paralelos:
  • Intensive pharmacosurveillance on infliximab in a general hospital
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To detect and to communicate the adverse reactions to infliximab in patients treated at our hospital during the year 2001. Method: Observational and retrospective study. Clinical histories were revised for the gathering of the necessary data: therapeutic indication, number of infusions, concomitant medication and adverse reactions to drugs (ARD). Results: 58 ARD were detected, presented in 57.5% of 40 patients being studied, that are classified as follows: Related to the infusion: 29 ARD. 32.5% of patients suffered at least some of these reactions. Related to the immunodepression: 17 ARD. 30.0% of patients presented some of these ARD. Other: 12 ARD, among which stood out two kinds of serum diseases. Conclusions: Generally, the high number of ARD detected and the gravity of some of them make necessary to continue to follow up these patients during the treatment period with this medication